drugset
drugset / Trial / NCT05366439

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

NCT05366439 ↗

Phase 1 Terminated 5 enrolled Atea Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

Timeline

Start
2022-04-22
Primary completion
2023-03-16
Completion
2023-03-16

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to deprioritize the dengue program”

Drugs

EvaluationDrugModalityDoseRoute
Subject AT-752 Other / unclassified — Oral

Indications

dengue disease